Mericitabine

Drug Profile

Mericitabine

Alternative Names: R-7128; RG 7128; RG7320; RO 5024048

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Pharmasset
  • Developer Roche
  • Class Antivirals; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action DNA-directed RNA polymerase inhibitors; Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 12 Feb 2016 Roche terminates a phase II trial in Hepatitis C in USA, Australia, Austria, Brazil, Canada, France, Germany, Italy, Mexico, New Zealand, Poland, Puerto Rico, Slovakia, Spain and United Kingdom due to decrease in percentage of participants (NCT01168856)
  • 28 Jan 2015 Discontinued - Phase-II for Hepatitis C (Combination therapy, Treatment-experienced) in Australia, Canada, USA, Brazil, Mexico, Germany, France, Spain, Puerto Rico, Poland, New Zealand, Slovakia, United Kingdom, Austria, Italy (PO)
  • 28 Jan 2015 Discontinued - Phase-II for Hepatitis C (Combination therapy, Treatment-naive) in Germany, France, Italy, Puerto Rico, Canada, USA, Australia, Poland, Austria, United Kingdom, Spain, New Zealand (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top